10-Q: Launch One Acquisition Corp. Advances Minovia Merger

Launch One Acquisition Corp. reports progress on its Minovia Therapeutics merger, extending bridge financing timelines while facing a going concern warning due to liquidity needs.

Summary

• Launch One Acquisition Corp. (SPAC) has entered into a Business Combination Agreement (BCA) with Minovia Therapeutics Ltd., an Israeli company, to merge and form a new publicly traded entity, Pubco, listed on Nasdaq.
• The total consideration for Minovia's security holders is $180 million plus net cash proceeds from Minovia's pre-closing financing activities, payable in Pubco ordinary shares.
• An earnout of an additional $57.5 million in Pubco ordinary shares is contingent on Pubco's share price reaching $11.50 or Minovia initiating a Phase 3 clinical trial within five years post-closing.
• The Sponsor's Founder Shares are subject to forfeiture if earnout conditions are not met.
• The company reported a net income of $1,922,018 for the three months ended June 30, 2025, and $4,209,431 for the six months ended June 30, 2025, primarily from interest earned on the Trust Account.
• Cash and marketable securities in the Trust Account increased to $240,554,492 as of June 30, 2025, from $235,529,521 at December 31, 2024.
• The redemption value per Class A Ordinary Share was approximately $10.46 as of June 30, 2025.
• General and administrative expenses significantly increased to $815,879 for the six months ended June 30, 2025, from $40,388 in the prior year period.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit 'going concern' warning and the reliance on future capital raises for the business combination to proceed. While a definitive merger agreement is a positive step for a SPAC, the significant financial uncertainties and the need for external financing for the target company overshadow this progress.

Positives

• Secured a definitive Business Combination Agreement with Minovia Therapeutics, a significant step for a SPAC.
• Reported net income of $1,922,018 for Q2 2025 and $4,209,431 for the six months ended June 30, 2025, driven by interest income from the Trust Account.
• The Trust Account balance has grown to $240,554,492, providing substantial capital for the business combination.
• The redemption value per Class A Ordinary Share has increased to approximately $10.46, indicating positive interest accrual for public shareholders.
• Minovia security holders are eligible for a significant earnout of $57.5 million based on future performance milestones.

Negatives

• The company has a "substantial doubt about its ability to continue as a going concern" due to liquidity needs and the mandatory liquidation date if the Business Combination is not completed.
• Operating cash balance is low at $263,740 as of June 30, 2025, down from $850,338 at December 31, 2024.
• Increased general and administrative expenses, reaching $815,879 for the six months ended June 30, 2025, reflecting costs associated with pursuing the acquisition.
• The company may need to raise additional capital through loans or investments, with no assurance of availability on commercially acceptable terms.
• Minovia's obligation to complete the closing is subject to a Minimum Cash Condition of $23 million, which includes Transaction Financing.

Risks

• Substantial doubt about the ability to continue as a going concern due to liquidity needs and the mandatory liquidation date if the Business Combination is not completed.
• Inability to complete the initial Business Combination within the Combination Period (by July 15, 2026) would force the company to cease operations and liquidate the Trust Account.
• The proceeds deposited in the Trust Account could become subject to claims of creditors, which could have priority over public shareholders.
• The Sponsor's indemnity obligations for third-party claims may not be satisfiable, as the Sponsor's only assets are company securities.
• The company's ability to complete a Business Combination may be adversely affected by various factors beyond its control, including changes in laws/regulations, financial market downturns, economic conditions, inflation, interest rate fluctuations, tariffs, supply chain disruptions, consumer confidence, public health, and geopolitical instability.
• Failure to meet the Nasdaq 36-Month Requirement could lead to suspension of trading and delisting.
• Minovia's obligation to close is subject to a Minimum Cash Condition of $23 million, which may not be met.
• Minovia's Bridge Financing of at least $5 million was extended, and failure to consummate it could lead to termination of the BCA.
• A negative Freedom to Operate (FTO) Opinion on Minovia's intellectual property could lead to termination of the BCA if no commercially reasonable mitigation plan is proposed.
• The company is an emerging growth company and has elected not to opt out of the extended transition period for new accounting standards, which may make financial comparisons difficult.

Future Outlook

The company expects to incur increased expenses as a public company and for due diligence related to its acquisition plans. It intends to use funds outside the Trust Account primarily to complete the Business Combination. The company may seek to extend the Combination Period beyond July 15, 2026, which would require shareholder approval and could affect its Nasdaq listing. The Minovia Business Combination is subject to various closing conditions, including a minimum cash condition and the successful consummation of bridge and additional transaction financing.

Management Comments

• We have neither engaged in any operations nor generated any revenues to date. Our only activities since February 21, 2024 (inception) through June 30, 2025 have been (i) organizational activities and (ii) activities relating to (x) the Initial Public Offering, (y) identifying and evaluating prospective acquisition candidates and activities in connection with the initial Business Combination and (z) consummating the Minovia Business Combination.
• We expect to incur increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance, among other things), as well as for due diligence expenses.
• Management has determined our liquidity condition, the date of mandatory liquidation and subsequent dissolution raise substantial doubt about our ability to continue as a going concern through twelve months from the date of the unaudited condensed financial statements and the notes thereto included in this Report under Item 1. Financial Statements were issued.

Industry Context

This filing is typical for a Special Purpose Acquisition Company (SPAC) nearing its deadline to complete a business combination. SPACs are shell companies that raise capital through an IPO with the sole purpose of acquiring an existing private company. The acquisition of Minovia Therapeutics, a biotech company, aligns with a trend of SPACs targeting high-growth, often capital-intensive, sectors like biotechnology. The challenges highlighted, such as the "going concern" warning and the need for additional financing, are common for SPACs as they navigate the complexities of de-SPAC transactions and the capital requirements of their target companies, especially in the biotech space where clinical trials demand significant funding. The extension of the bridge financing timeline for Minovia reflects the difficulties in securing capital in the current market environment.

Comparison to Industry Standards

• The company's structure and operational phase are standard for a SPAC, with no operating revenues and primary activities focused on identifying and executing a business combination.
• The increase in the Trust Account value from $10.00 per unit at IPO to approximately $10.46 per share as of June 30, 2025, is consistent with typical SPAC operations, where interest accrues on the funds held in trust.
• The "going concern" warning is a common disclosure for SPACs that have not yet completed a business combination and face a liquidation deadline, reflecting the inherent uncertainty in their business model. Many SPACs face similar liquidity challenges for their operating expenses outside the trust.
• The deferred underwriting fee of $10,950,000, payable upon business combination completion, is a standard SPAC cost structure, aligning with industry practices for underwriting compensation.
• The requirement for Minovia to secure bridge financing and additional transaction financing (totaling at least $23 million for the Minimum Cash Condition) is typical for de-SPAC transactions involving capital-intensive target companies like biotech firms, where significant capital is needed for R&D and clinical development. For example, other biotech SPAC mergers like those involving Ginkgo Bioworks (via Soaring Eagle Acquisition Corp.) or 23andMe (via VG Acquisition Corp.) also involved significant PIPE (Private Investment in Public Equity) or other financing components to meet capital needs and closing conditions.
• The earnout structure for Minovia security holders, contingent on share price or clinical trial milestones, is a common mechanism in SPAC deals to align incentives and provide future upside to the target company's founders and early investors.

Corporate Governance

Legal Proceedings

• To the knowledge of our Management Team, there is no material litigation currently pending or contemplated against us, any of our officers or directors in their capacity as such or against any of our property.

Related Party Transactions

• The Sponsor made a capital contribution of $25,000 for 5,750,000 Class B Ordinary Shares (Founder Shares).
• The Sponsor agreed to loan the company up to $340,000 via an IPO Promissory Note (no borrowings outstanding as of June 30, 2025).
• The company owes the Sponsor $27,340 due to an excess payment.
• An affiliate of the Sponsor receives $12,500 per month for administrative support services (totaling $37,500 for Q2 2025 and $75,000 for the six months ended June 30, 2025).
• The Sponsor or its affiliates or certain officers/directors may provide Working Capital Loans, up to $1,500,000, convertible into warrants.

Stakeholder Impact

• Shareholders (Public): Entitled to redeem shares at ~$10.46 per share if the Business Combination is not completed or if they vote against certain amendments. Their investment is held in the Trust Account, earning interest. They face the risk of liquidation if the deal fails and potential dilution from future capital raises.
• Shareholders (Sponsor/Founder): Their Founder Shares are subject to forfeiture if earnout conditions are not met, aligning their interests with the success of the combined entity. They waive redemption rights for their Founder Shares.
• Minovia Security Holders: Will receive Pubco ordinary shares as consideration and have contingent rights to additional Earnout Shares based on performance milestones, providing potential future upside.
• Employees (Minovia Management): Expected to enter into employment agreements with Pubco, indicating continuity and integration into the new public entity.
• Creditors: The Trust Account proceeds could become subject to claims of creditors, potentially having priority over public shareholders in a liquidation scenario.
• Underwriters: Entitled to a deferred underwriting fee of $10,950,000 upon completion of the Business Combination.

Next Steps

• Complete the Minovia Business Combination, subject to various closing conditions.
• Minovia to seek and consummate bridge financing of at least $5 million within 60 days of BCA execution.
• Company, Minovia, and Pubco to seek additional transaction financing of at least $18 million.
• File a Registration Statement on Form F-4 (Minovia Business Combination Registration Statement) with the SEC, including a proxy statement/prospectus.
• Obtain Company and Minovia shareholder approvals for the Business Combination.
• Obtain Nasdaq approval for Pubco ordinary shares listing.
• Appoint the post-Closing Pubco board of directors (8 directors: 5 Minovia-designated, 1 Sponsor-designated, 2 designated by Alex Greystoke and Jon Bakhshi).
• Amend and restate Pubco's organizational documents.
• Amend and restate the Registration Rights Agreement for Pubco securities and certain Minovia security holders.
• Secure certain employment agreements between Pubco and Minovia management.
• Obtain Lock-Up Agreements from certain Minovia security holders.
• Receive certain Israeli tax rulings and Israeli securities laws rulings.
• Conclude statutory merger waiting periods under Israeli law.
• Form SPAC Merger Sub and execute a joinder agreement to the Minovia BCA.
• Potentially seek to extend the Combination Period beyond July 15, 2026, requiring Public Shareholder approval.

Key Dates

Recommendation

While a definitive business combination agreement is a positive step for a SPAC, the explicit "substantial doubt about our ability to continue as a going concern" due to insufficient operating capital and the reliance on future, uncertain capital raises for Minovia (Bridge Financing and Additional Transaction Financing) present significant risks. The company's operating cash is dwindling, and failure to secure the necessary financing or complete the merger by the deadline would lead to liquidation. This high level of uncertainty and the explicit going concern warning make the stock a high-risk proposition, suggesting a "sell" or "avoid" stance for a seasoned investor until these fundamental liquidity and deal completion risks are substantially mitigated.

Keywords

SPAC, Special Purpose Acquisition Company, Minovia Therapeutics, Business Combination, Merger, Biotech, Healthcare, Nasdaq Listing, 10-Q, Quarterly Report, SEC Filing, Going Concern, Trust Account, Earnout, Bridge Financing, Mitochondrial Disease